241 related articles for article (PubMed ID: 28295194)
21. Selective Tyk2 inhibitors as potential therapeutic agents: a patent review (2015-2018).
He X; Chen X; Zhang H; Xie T; Ye XY
Expert Opin Ther Pat; 2019 Feb; 29(2):137-149. PubMed ID: 30621465
[TBL] [Abstract][Full Text] [Related]
22. PI3K pan-inhibition impairs more efficiently proliferation and survival of T-cell acute lymphoblastic leukemia cell lines when compared to isoform-selective PI3K inhibitors.
Lonetti A; Cappellini A; Spartà AM; Chiarini F; Buontempo F; Evangelisti C; Evangelisti C; Orsini E; McCubrey JA; Martelli AM
Oncotarget; 2015 Apr; 6(12):10399-414. PubMed ID: 25871383
[TBL] [Abstract][Full Text] [Related]
23. TYK2 Variants in B-Acute Lymphoblastic Leukaemia.
Turrubiartes-Martínez E; Bodega-Mayor I; Delgado-Wicke P; Molina-Jiménez F; Casique-Aguirre D; González-Andrade M; Rapado I; Camós M; Díaz-de-Heredia C; Barragán E; Ramírez-Orellana M; Aguado B; Figuera Á; Martínez-López J; Fernández-Ruiz E
Genes (Basel); 2020 Nov; 11(12):. PubMed ID: 33260630
[TBL] [Abstract][Full Text] [Related]
24. PSEN1-selective gamma-secretase inhibition in combination with kinase or XPO-1 inhibitors effectively targets T cell acute lymphoblastic leukemia.
Govaerts I; Prieto C; Vandersmissen C; Gielen O; Jacobs K; Provost S; Nittner D; Maertens J; Boeckx N; De Keersmaecker K; Segers H; Cools J
J Hematol Oncol; 2021 Jun; 14(1):97. PubMed ID: 34167562
[TBL] [Abstract][Full Text] [Related]
25. Effect of ethanol on innate antiviral pathways and HCV replication in human liver cells.
Plumlee CR; Lazaro CA; Fausto N; Polyak SJ
Virol J; 2005 Dec; 2():89. PubMed ID: 16324217
[TBL] [Abstract][Full Text] [Related]
26. Resveratrol induces apoptosis and autophagy in T-cell acute lymphoblastic leukemia cells by inhibiting Akt/mTOR and activating p38-MAPK.
Ge J; Liu Y; Li Q; Guo X; Gu L; Ma ZG; Zhu YP
Biomed Environ Sci; 2013 Nov; 26(11):902-11. PubMed ID: 24331535
[TBL] [Abstract][Full Text] [Related]
27. Tyrosine Kinase 2 Signalling Drives Pathogenic T cells in Colitis.
De Vries LCS; Ghiboub M; van Hamersveld PHP; Welting O; Verseijden C; Bell MJ; Rioja I; Prinjha RK; Koelink PJ; Strobl B; Müller M; D'Haens GR; Wildenberg ME; De Jonge WJ
J Crohns Colitis; 2021 Apr; 15(4):617-630. PubMed ID: 33005945
[TBL] [Abstract][Full Text] [Related]
28. Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165.
Wrobleski ST; Moslin R; Lin S; Zhang Y; Spergel S; Kempson J; Tokarski JS; Strnad J; Zupa-Fernandez A; Cheng L; Shuster D; Gillooly K; Yang X; Heimrich E; McIntyre KW; Chaudhry C; Khan J; Ruzanov M; Tredup J; Mulligan D; Xie D; Sun H; Huang C; D'Arienzo C; Aranibar N; Chiney M; Chimalakonda A; Pitts WJ; Lombardo L; Carter PH; Burke JR; Weinstein DS
J Med Chem; 2019 Oct; 62(20):8973-8995. PubMed ID: 31318208
[TBL] [Abstract][Full Text] [Related]
29. Targeting serine hydroxymethyltransferases 1 and 2 for T-cell acute lymphoblastic leukemia therapy.
Pikman Y; Ocasio-Martinez N; Alexe G; Dimitrov B; Kitara S; Diehl FF; Robichaud AL; Conway AS; Ross L; Su A; Ling F; Qi J; Roti G; Lewis CA; Puissant A; Vander Heiden MG; Stegmaier K
Leukemia; 2022 Feb; 36(2):348-360. PubMed ID: 34341479
[TBL] [Abstract][Full Text] [Related]
30. Notch3-mediated regulation of MKP-1 levels promotes survival of T acute lymphoblastic leukemia cells.
Masiero M; Minuzzo S; Pusceddu I; Moserle L; Persano L; Agnusdei V; Tosello V; Basso G; Amadori A; Indraccolo S
Leukemia; 2011 Apr; 25(4):588-98. PubMed ID: 21263446
[TBL] [Abstract][Full Text] [Related]
31. Targeting BET proteins improves the therapeutic efficacy of BCL-2 inhibition in T-cell acute lymphoblastic leukemia.
Peirs S; Frismantas V; Matthijssens F; Van Loocke W; Pieters T; Vandamme N; Lintermans B; Dobay MP; Berx G; Poppe B; Goossens S; Bornhauser BC; Bourquin JP; Van Vlierberghe P
Leukemia; 2017 Oct; 31(10):2037-2047. PubMed ID: 28074072
[TBL] [Abstract][Full Text] [Related]
32. Design of a peptide inhibitor of tyrosine kinase 2.
Works MG; Song B; Kibler P; Tanga MJ; Galande AK; D'Andrea A
Protein Pept Lett; 2014 May; 21(5):419-25. PubMed ID: 24304386
[TBL] [Abstract][Full Text] [Related]
33. Activity of the pan-class I phosphoinositide 3-kinase inhibitor NVP-BKM120 in T-cell acute lymphoblastic leukemia.
Lonetti A; Antunes IL; Chiarini F; Orsini E; Buontempo F; Ricci F; Tazzari PL; Pagliaro P; Melchionda F; Pession A; Bertaina A; Locatelli F; McCubrey JA; Barata JT; Martelli AM
Leukemia; 2014 Jun; 28(6):1196-206. PubMed ID: 24310736
[TBL] [Abstract][Full Text] [Related]
34. In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia.
Iacobucci I; Di Rorà AG; Falzacappa MV; Agostinelli C; Derenzini E; Ferrari A; Papayannidis C; Lonetti A; Righi S; Imbrogno E; Pomella S; Venturi C; Guadagnuolo V; Cattina F; Ottaviani E; Abbenante MC; Vitale A; Elia L; Russo D; Zinzani PL; Pileri S; Pelicci PG; Martinelli G
J Hematol Oncol; 2015 Nov; 8():125. PubMed ID: 26542114
[TBL] [Abstract][Full Text] [Related]
35. CEP-28122, a highly potent and selective orally active inhibitor of anaplastic lymphoma kinase with antitumor activity in experimental models of human cancers.
Cheng M; Quail MR; Gingrich DE; Ott GR; Lu L; Wan W; Albom MS; Angeles TS; Aimone LD; Cristofani F; Machiorlatti R; Abele C; Ator MA; Dorsey BD; Inghirami G; Ruggeri BA
Mol Cancer Ther; 2012 Mar; 11(3):670-9. PubMed ID: 22203728
[TBL] [Abstract][Full Text] [Related]
36. Anti-adult T‑cell leukemia/lymphoma activity of cerdulatinib, a dual SYK/JAK kinase inhibitor.
Ishikawa C; Senba M; Mori N
Int J Oncol; 2018 Oct; 53(4):1681-1690. PubMed ID: 30066853
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of IRAK1/4 sensitizes T cell acute lymphoblastic leukemia to chemotherapies.
Li Z; Younger K; Gartenhaus R; Joseph AM; Hu F; Baer MR; Brown P; Davila E
J Clin Invest; 2015 Mar; 125(3):1081-97. PubMed ID: 25642772
[TBL] [Abstract][Full Text] [Related]
38. Discovery of Tyk2 inhibitors via the virtual site-directed fragment-based drug design.
Jang WD; Kim JT; Son HY; Park SY; Cho YS; Koo TS; Lee H; Kang NS
Bioorg Med Chem Lett; 2015 Sep; 25(18):3947-52. PubMed ID: 26231159
[TBL] [Abstract][Full Text] [Related]
39. Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235.
Hall CP; Reynolds CP; Kang MH
Clin Cancer Res; 2016 Feb; 22(3):621-32. PubMed ID: 26080839
[TBL] [Abstract][Full Text] [Related]
40. Dual inhibition of class IA phosphatidylinositol 3-kinase and mammalian target of rapamycin as a new therapeutic option for T-cell acute lymphoblastic leukemia.
Chiarini F; Falà F; Tazzari PL; Ricci F; Astolfi A; Pession A; Pagliaro P; McCubrey JA; Martelli AM
Cancer Res; 2009 Apr; 69(8):3520-8. PubMed ID: 19351820
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
